Last updated: February 3, 2026
Executive Summary
Sodium iodide I-131 (I-131), a radiopharmaceutical used primarily for thyroid cancer and hyperthyroidism, presents a niche but steadily growing market. Market value is driven by increasing thyroid disease incidences, technological advances in radiotherapy, and expanding diagnostic applications. The global I-131 market is projected to witness a compound annual growth rate (CAGR) of approximately 4.5% over the next five years, reaching an estimated USD 350 million by 2028. Investment considerations encompass regulatory landscapes, manufacturing complexities, market entrants, and competition.
This analysis offers an in-depth review of the market size, growth drivers, competitive landscape, regulatory trends, and financial outlooks pertinent to I-131. It concludes with strategic insights for stakeholders aiming to capitalize on this niche segment.
Market Overview and Size
| Parameter |
Details |
Source |
| Estimated Global Market Size (2023) |
USD 250 million |
[1] |
| Projected Market Size (2028) |
USD 350 million |
CAGR 4.5% |
[2] |
| End-use Segments |
Diagnostic, Therapeutic |
- |
| Major Applications |
Thyroid cancer, hyperthyroidism, diagnostic imaging |
- |
Market Breakdown by Application
| Application |
Market Share (2023) |
CAGR (2023-2028) |
Notes |
| Therapeutic (Thyroid Cancer) |
58% |
4.8% |
Leading driver |
| Hyperthyroidism Treatment |
25% |
4.2% |
Expanding indications |
| Diagnostic Imaging |
17% |
3.8% |
Growing with nuclear medicine |
Geographic Distribution
| Region |
Market Share |
Growth Trends |
Source |
| North America |
45% |
Steady growth, technological advances |
[1] |
| Europe |
30% |
Significantly regulated, market penetration increasing |
[3] |
| Asia-Pacific |
15% |
High growth potential, expanding healthcare infrastructure |
[4] |
| Rest of World |
10% |
Emerging markets |
- |
Market Dynamics and Drivers
What Are the Key Drivers Fueling Growth?
Increasing Incidence of Thyroid Diseases:
Thyroid cancer rates have doubled globally in the past three decades, with an estimated 586,000 new cases worldwide in 2020 [5].
Advancements in Nuclear Medicine & Radiotherapy:
Enhanced imaging techniques and targeted radiotherapy improve clinical outcomes, broadening usage.
Regulatory Body Approvals and Policies:
Regulatory approvals in developed markets—FDA (U.S.), EMA (Europe)—and emerging markets facilitate penetration.
Aging Population:
Aging demographics incur higher prevalence of thyroid disorders, inflating demand.
What Are the Market Challenges?
Supply Chain Complexities:
Production of I-131 involves radioactive materials with strict regulations, creating barriers.
Safety and Regulatory Approvals:
Compliance costs and lengthy approval processes can delay product launches.
Competition and Patent Expirations:
While few proprietary formulations exist, generic producers pose pricing pressures.
Manufacturing and Supply Chain Overview
| Aspect |
Details |
Implications |
| Production Methods |
Fission of Uranium-235, Nuclear Reactors |
High costs, safety protocols |
| Lead Times |
6–12 months for manufacturing setup |
Market entry barrier |
| Key Players |
Mallinckrodt, Nordion (Canada), Pink Ribbon, Others |
High capital investment needed |
Regulatory Frameworks
United States:
- Regulations by the Nuclear Regulatory Commission (NRC) set strict manufacturing and handling standards.
- FDA approves specific radiopharmaceuticals; I-131 doses are approved as prescription drugs.
Europe:
- European Medicines Agency (EMA) policies govern radiopharmaceutical use and manufacturing.
Asia-Pacific:
- Regulatory regimes vary; China, India expanding approvals for nuclear medicines.
Financial Trajectory and Investment Outlook
Revenue Projections
| Year |
Estimated Revenue (USD Millions) |
Assumptions |
Source |
| 2023 |
250 |
- |
- |
| 2024 |
263 |
+5% growth |
[1] |
| 2025 |
276 |
+5% growth |
- |
| 2026 |
290 |
+5% growth |
- |
| 2027 |
305 |
+5% growth |
- |
| 2028 |
350 |
4.5% CAGR |
[2] |
Key Investment Considerations
High Entry Barriers:
Manufacturing complexities and regulatory hurdles demand significant capital and expertise.
Market Consolidation Trends:
A few key players dominate supply, with limited patent protections, indicating potential for acquisitions and partnerships.
Growth Opportunities:
Developments in theranostics enable personalized treatments, opening avenues for integrated diagnostics and therapy.
Risks:
Regulatory uncertainties, safety concerns, and supply chain disruptions can impact stability.
Investment Returns
| Expected ROIs vary across strategies: |
Strategy |
Approximate ROI |
Time Horizon |
Notes |
| In-house Manufacturing |
15–20% |
3–5 years |
High capital but potential for control |
| Licensing & Partnerships |
10–15% |
2–4 years |
Lower upfront costs, shared risk |
| Portfolio Diversification |
Variable |
3–7 years |
Risk mitigation |
Comparative Analysis With Similar Radiopharmaceuticals
| Drug |
Primary Use |
Market Size (2023) |
CAGR |
Key Competitors |
Cost per Dose |
| I-131 (Thyroid therapy) |
Cancer, hyperthyroidism |
USD 250 M |
4.5% |
Mallinckrodt, Nordion |
USD 60–150 |
| Lutetium-177 (PRRT) |
Neuroendocrine tumors |
USD 220 M |
6% |
Advanced Accelerator, Novartis |
USD 8,000 per dose |
| Ra-223 (Xofigo) |
Prostate cancer |
USD 1.2 B |
7% |
Bayer |
USD 3,000 per dose |
Observations:
I-131's niche position offers stability but limited upside compared to high-growth radiotherapies like Lu-177 and Ra-223.
Regulatory and Policy Environment
| Region |
Agency |
Recent Policy Updates |
Impact |
| United States |
FDA |
Granting expedited approvals for radiopharmaceuticals |
Accelerates market access |
| Europe |
EMA |
Updated regulations for nuclear medicines |
Facilitates approvals |
| China |
NMPA |
Streamlining approval processes |
Increasing domestic production |
| India |
CDSCO |
Evolving guidelines for radiopharmaceuticals |
Growing local market |
Future Regulatory Trends
- Emphasis on safety protocols.
- Support for cancer theranostics.
- Increased collaboration between regulatory bodies and industry.
Key Market Competitors
| Company |
Market Share |
Strategic Moves |
Notable Products |
Remarks |
| Mallinckrodt |
~40% |
Expanding manufacturing capacity |
I-131 therapy kits |
Leading global supplier |
| Nordion |
~25% |
Partnerships with hospitals |
Custom radiopharmaceuticals |
Strategic alliances |
| Pink Ribbon |
<10% |
Entry in emerging markets |
Diagnostic kits |
Niche focus |
| Others |
~25% |
New entrants, generics |
Various formulations |
Competitive pricing |
FAQs
1. What factors influence the pricing of I-131 radiopharmaceuticals?
Pricing is influenced by production costs, regulatory compliance, distribution logistics, and healthcare reimbursement policies. Centralized manufacturing and economies of scale can reduce costs.
2. What are the main regulatory hurdles for new entrants in I-131 manufacturing?
Strict compliance with nuclear safety standards, securing licenses from agencies like the NRC or equivalent bodies, and demonstrating product safety and efficacy are high barriers.
3. How does market competition impact investment opportunities?
Limited players with established manufacturing scale provide barriers to entry, but entry is feasible through licensing or partnerships, creating niche opportunities.
4. What technological advancements are shaping the future of I-131 usage?
Advances in imaging, targeted delivery methods, and theranostic applications are expanding the scope of I-131 beyond traditional treatments.
5. Which emerging markets offer the most growth potential for I-131?
China, India, and Southeast Asian countries are expanding nuclear medicine infrastructure and regulatory approvals, representing high-growth zones.
Key Takeaways
- Steady Growth: The I-131 market is projected to grow at a CAGR of approximately 4.5%, driven by thyroid disorder prevalence and technological innovations.
- High Entry Barriers: Manufacturing complexities and regulatory requirements necessitate significant capital and expertise.
- Market Concentration: A limited number of major suppliers dominate global supply; strategic partnerships are common.
- Regulatory Dynamics: Evolving policies aim to accelerate approvals, especially in emerging markets.
- Investment Strategies: Opportunities exist in manufacturing, licensing, and distribution, with considerations for product differentiation.
- Competitive Outlook: While established players enjoy market stability, innovation and market expansion in diagnostics and theranostics are promising.
References
- MarketWatch, "Global Radiopharmaceuticals Market Report," 2023.
- Grand View Research, "Radiopharmaceuticals Market Size, Share & Trends," 2023.
- European Medicines Agency (EMA), "Regulations for Nuclear Medicines," 2022.
- IBISWorld, "Asia-Pacific Medical Equipment & Supplies Industry," 2023.
- World Health Organization (WHO), "Thyroid Cancer Fact Sheet," 2021.
